EAL®

EAL^® is a multi-target cellular immunotherapy product with more than a decade of track record of clinical application in the treatment of cancer. It is a preparation of activated and expanded T cells originally taken from a patient’s autologous peripheral blood and cultured using our patented methods. The main active component of the product is CD3+ CD8+ cytotoxic T cells.The efficacy of activated autologous lymphocytes (AAL) therapy (of which EAL^® is an example) in the prevention of postsurgical recurrence of liver cancer has been seen in overseas clinical trials. Separately, the safety and efficacy of EAL^® produced using our patented methods in the treatment of tumours have been reported in three SCI academic journal articles.